JP2007508353A5 - - Google Patents

Download PDF

Info

Publication number
JP2007508353A5
JP2007508353A5 JP2006534713A JP2006534713A JP2007508353A5 JP 2007508353 A5 JP2007508353 A5 JP 2007508353A5 JP 2006534713 A JP2006534713 A JP 2006534713A JP 2006534713 A JP2006534713 A JP 2006534713A JP 2007508353 A5 JP2007508353 A5 JP 2007508353A5
Authority
JP
Japan
Prior art keywords
mol
pharmaceutical composition
cationic liposome
paclitaxel
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006534713A
Other languages
English (en)
Japanese (ja)
Other versions
JP5645340B2 (ja
JP2007508353A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2004/011655 external-priority patent/WO2005039533A1/en
Publication of JP2007508353A publication Critical patent/JP2007508353A/ja
Publication of JP2007508353A5 publication Critical patent/JP2007508353A5/ja
Application granted granted Critical
Publication of JP5645340B2 publication Critical patent/JP5645340B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006534713A 2003-10-15 2004-10-15 活性成分を含有するカチオンリポソームの投与方法 Expired - Fee Related JP5645340B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP03023539.4 2003-10-15
EP03023539 2003-10-15
EP04000361.8 2004-01-09
EP04000361 2004-01-09
PCT/EP2004/011655 WO2005039533A1 (en) 2003-10-15 2004-10-15 Method of administering cationic liposomes comprising an active drug

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012159071A Division JP2012229255A (ja) 2003-10-15 2012-07-17 活性成分を含有するカチオンリポソームの投与方法

Publications (3)

Publication Number Publication Date
JP2007508353A JP2007508353A (ja) 2007-04-05
JP2007508353A5 true JP2007508353A5 (enExample) 2007-12-06
JP5645340B2 JP5645340B2 (ja) 2014-12-24

Family

ID=34524705

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006534713A Expired - Fee Related JP5645340B2 (ja) 2003-10-15 2004-10-15 活性成分を含有するカチオンリポソームの投与方法
JP2012159071A Pending JP2012229255A (ja) 2003-10-15 2012-07-17 活性成分を含有するカチオンリポソームの投与方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012159071A Pending JP2012229255A (ja) 2003-10-15 2012-07-17 活性成分を含有するカチオンリポソームの投与方法

Country Status (11)

Country Link
US (1) US20080063699A1 (enExample)
EP (2) EP2286794B8 (enExample)
JP (2) JP5645340B2 (enExample)
AU (1) AU2004283464B8 (enExample)
CA (1) CA2542217C (enExample)
DK (1) DK2286794T3 (enExample)
ES (1) ES2574231T3 (enExample)
HU (1) HUE028648T2 (enExample)
PL (1) PL2286794T3 (enExample)
PT (1) PT2286794T (enExample)
WO (1) WO2005039533A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US20050255154A1 (en) 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
WO2006089290A1 (en) 2005-02-18 2006-08-24 Abraxis Bioscience Inc.. Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US9233094B2 (en) 2005-05-04 2016-01-12 Medigene Ag Method of administering a cationic liposomal preparation
BRPI0615032A2 (pt) * 2005-09-01 2011-04-26 Biolipox Ab composição farmacêutica, processo para a preparação da mesma, e, uso de uma composição
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
KR100658436B1 (ko) * 2005-12-09 2006-12-27 한국화학연구원 아데노실코발라민 함유 피부질환 치료용 외용제 조성물
AU2007228984B2 (en) * 2006-03-22 2012-05-03 Syncore Biotechnology Co., Ltd Treatment of triple receptor negative breast cancer
EP2040674B1 (en) * 2006-05-18 2010-07-07 MediGene AG Cationic liposomal preparations for the treatment of rheumatoid arthritis
WO2011123393A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
NZ602385A (en) 2010-03-29 2014-08-29 Abraxis Bioscience Llc Methods of treating cancer
EP2394640A1 (en) 2010-05-21 2011-12-14 MediGene AG Improved liposomal formulations of lipophilic compounds
KR20130088116A (ko) 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
US9144575B2 (en) 2010-07-28 2015-09-29 Life Technologies Corporation Anti-viral azide containing compounds
WO2012075210A2 (en) * 2010-12-01 2012-06-07 Niiki Pharma Inc. Method for treating refractory cancer
PL3892295T3 (pl) 2011-05-24 2023-07-24 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe
SG11201404361UA (en) 2012-01-26 2014-09-26 Life Technologies Corp Methods for increasing the infectivity of viruses
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
EP2925348B1 (en) 2012-11-28 2019-03-06 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
DE102013009744A1 (de) * 2013-03-26 2014-10-02 Forschungszentrum Jülich GmbH Fusionsmischung zur lipidhaltigen Membranmodifikation einer beliebigen Lipidmembran, einer Zellmembran, einem Bestandteil einer Zellmembran oder einer von den übrigen Zell- Bestandteilen getrennten Zellmembran in vivo oder in vitro
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
JP6921759B2 (ja) 2015-06-04 2021-08-18 クリティテック・インコーポレイテッド 捕集装置および使用法
AU2016323770A1 (en) 2015-09-16 2018-03-29 Dfb Soria, Llc Delivery of drug nanoparticles and methods of use thereof
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
SG10201913409VA (en) 2016-04-04 2020-03-30 Crititech Inc Methods for solid tumor treatment
US20190343763A1 (en) * 2016-11-11 2019-11-14 Western University Of Health Sciences Methods of treating upper tract urothelial carcinomas
TWI852903B (zh) 2017-01-05 2024-08-21 杏國新藥股份有限公司 胰臟癌治療
JP2020514359A (ja) 2017-03-15 2020-05-21 ディーエフビー ソリア リミテッド ライアビリティ カンパニー タキサンのナノ粒子を用いる皮膚悪性腫瘍処置のための局所療法
SG11201909840TA (en) 2017-06-09 2019-11-28 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
CN115919815A (zh) 2017-06-14 2023-04-07 克里蒂泰克公司 治疗肺部疾病的方法
KR20200064112A (ko) 2017-10-03 2020-06-05 크리티테크, 인크. 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
KR20200132963A (ko) 2018-03-16 2020-11-25 디에프비 소리아, 엘엘씨 탁산의 나노입자를 사용하는 자궁경부 상피내 신생물 (cin) 및 자궁경부 암의 치료를 위한 국소적 요법
KR20250126139A (ko) * 2023-01-31 2025-08-22 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 종양을 치료하는 파클리탁셀 양이온성 리포솜의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1254135B (it) 1992-01-16 1995-09-08 Sigma Tau Ind Farmaceuti Esteri di acil carnitine con alcooli alifatici a lunga catena e composizioni farmaceutiche che li contengono, ad attivita' antibatterica.
DE69329073T2 (de) * 1992-03-23 2001-01-18 Georgetown University, Washington In liposomen verkapseltes taxol und verwendungsverfahren
DE4430593C2 (de) * 1994-08-20 1999-01-14 Max Delbrueck Centrum Verfahren zur Herstellung von Liposomal verkapseltem Taxol
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US7314637B1 (en) * 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
HK1046506B (en) * 1999-09-09 2006-08-25 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
UY27185A1 (es) * 2001-02-28 2002-09-30 Bristol Myers Squibb Co Dosificación metronómica de taxanos
JP4975964B2 (ja) * 2002-06-26 2012-07-11 メディゲーネ アクチエンゲゼルシャフト 脂肪親和性化合物から成る陽イオン性リポソームの製法
WO2004002455A1 (en) * 2002-06-26 2004-01-08 Medigene Oncology Gmbh Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system

Similar Documents

Publication Publication Date Title
Choy et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer.
JP5704788B2 (ja) 癌の治療および過剰増殖性疾患の治療のための、免疫遺伝子療法と化学療法の組み合わせ
JP2018528184A5 (enExample)
JP5645340B2 (ja) 活性成分を含有するカチオンリポソームの投与方法
JP2011144190A (ja) 抗癌剤の効果増強剤
CA2412795A1 (en) Improved liposomal camptothecins and uses thereof
CN115487187B (zh) 一种用于治疗胃癌的喹啉衍生物
JP6855488B2 (ja) 食道癌を治療するためのキノリン誘導体の使用とその治療方法、医薬組成物及びキット
TWI522105B (zh) 偏亞砷酸鈉於治療癌疼痛及炎症之用途
JP2023546362A5 (enExample)
CN101687104A (zh) 包括长春氟宁和曲妥单抗的癌症治疗联合疗法
JP2009536956A (ja) 抗癌治療法
JP2008540364A5 (enExample)
CN102438608A (zh) 包含ave8062和索拉非尼的抗肿瘤组合
O'Shaughnessy et al. Current status of paclitaxel in the treatment of breast cancer
CA2483826A1 (en) Epothilone derivative for the treatment of hepatoma and other cancer diseases
CN101652138A (zh) 1-取代芳基-2(1h)-吡啶酮化合物的新医药用途
Tralongo et al. Chemotherapy in frail elderly patients with hormone-refractory prostate cancer: A “real world” experience
JP2006523664A5 (enExample)
Kuo et al. Functionalized drug-gene delivery materials to transport inhibitor of apoptosis protein antagonists for tumor malignancy management
CN113993515B (zh) 使用藏红花酸治疗实体肿瘤的方法
EP2826482A1 (en) Novel antitumor agent comprising combination of three agents
KR20140022856A (ko) 치료적 요법
JPWO2015152407A1 (ja) 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤
KR20160009677A (ko) 암 치료를 위한 ro5503781, 카페시타빈과 옥살리플라틴의 조합